Cargando…
Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints
Lowering of prion protein (PrP) expression in the brain is a genetically validated therapeutic hypothesis in prion disease. We recently showed that antisense oligonucleotide (ASO)-mediated PrP suppression extends survival and delays disease onset in intracerebrally prion-infected mice in both prophy...
Autores principales: | Minikel, Eric Vallabh, Zhao, Hien T, Le, Jason, O’Moore, Jill, Pitstick, Rose, Graffam, Samantha, Carlson, George A, Kavanaugh, Michael P, Kriz, Jasna, Kim, Jae Beom, Ma, Jiyan, Wille, Holger, Aiken, Judd, McKenzie, Deborah, Doh-ura, Katsumi, Beck, Matthew, O’Keefe, Rhonda, Stathopoulos, Jacquelyn, Caron, Tyler, Schreiber, Stuart L, Carroll, Jeffrey B, Kordasiewicz, Holly B, Cabin, Deborah E, Vallabh, Sonia M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641729/ https://www.ncbi.nlm.nih.gov/pubmed/32776089 http://dx.doi.org/10.1093/nar/gkaa616 |
Ejemplares similares
-
Therapeutic Trial of anle138b in Mouse Models of Genetic Prion Disease
por: Vallabh, Sonia M., et al.
Publicado: (2023) -
A single-cell map of antisense oligonucleotide activity in the brain
por: Mortberg, Meredith A, et al.
Publicado: (2023) -
Antisense oligonucleotides extend survival of prion-infected mice
por: Raymond, Gregory J., et al.
Publicado: (2019) -
Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides
por: Reidenbach, Andrew G., et al.
Publicado: (2019) -
Analysis of non-human primate models for evaluating prion disease therapeutic efficacy
por: Mortberg, Meredith A., et al.
Publicado: (2022)